Stonebridge Capital Advisors LLC boosted its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 3.7% during the first quarter, Holdings Channel reports. The institutional investor owned 37,969 shares of the medical research company’s stock after buying an additional 1,338 shares during the period. Thermo Fisher Scientific makes up about 1.6% of Stonebridge Capital Advisors LLC’s investment portfolio, making the stock its 17th largest position. Stonebridge Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $5,832,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in TMO. Independent Portfolio Consultants Inc. boosted its position in shares of Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock valued at $112,000 after buying an additional 2 shares in the last quarter. Sharkey Howes & Javer raised its stake in shares of Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after buying an additional 7 shares during the last quarter. FNY Managed Accounts LLC bought a new stake in shares of Thermo Fisher Scientific during the first quarter valued at approximately $153,000. Penserra Capital Management LLC raised its stake in shares of Thermo Fisher Scientific by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,150 shares of the medical research company’s stock valued at $176,000 after buying an additional 100 shares during the last quarter. Finally, Investment Centers of America Inc. bought a new stake in shares of Thermo Fisher Scientific during the first quarter valued at approximately $200,000. 87.60% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Inc (TMO) traded up 0.35% during midday trading on Tuesday, hitting $174.64. 353,857 shares of the company traded hands. The stock has a 50 day moving average of $176.77 and a 200 day moving average of $166.03. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $182.87. The stock has a market cap of $68.13 billion, a P/E ratio of 30.43 and a beta of 1.06.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.27 by $0.03. The firm had revenue of $5 billion for the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. Thermo Fisher Scientific’s revenue was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.03 earnings per share. Equities research analysts predict that Thermo Fisher Scientific Inc will post $9.24 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be issued a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is currently 10.45%.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/stonebridge-capital-advisors-llc-purchases-1338-shares-of-thermo-fisher-scientific-inc-tmo/1491190.html.

Several equities research analysts have commented on TMO shares. Bank of America Corporation restated a “buy” rating and set a $210.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Barclays PLC set a $175.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Wednesday, April 26th. Cantor Fitzgerald started coverage on shares of Thermo Fisher Scientific in a research report on Thursday, May 18th. They set an “overweight” rating and a $194.00 target price on the stock. Finally, Cowen and Company restated an “outperform” rating and set a $185.00 target price (up from $175.00) on shares of Thermo Fisher Scientific in a research report on Saturday, April 29th. One analyst has rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $188.56.

In related news, CEO Marc N. Casper sold 20,000 shares of the stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total value of $3,455,800.00. Following the completion of the transaction, the chief executive officer now owns 269,279 shares in the company, valued at approximately $46,528,718.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction on Monday, June 5th. The shares were sold at an average price of $176.26, for a total value of $440,650.00. Following the completion of the transaction, the chief financial officer now owns 37,790 shares of the company’s stock, valued at approximately $6,660,865.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 27,188 shares of company stock worth $4,702,223. 0.49% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.